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Molecular subtyping was used to investigate the epidemiology of human T-lymphotropic virus type II (HTLV-II) in the United
States. Nested polymerase chain reaction of the HTLV-II long terminal repeat region followed by restriction fragment length
polymorphism (RFLP) analysis was performed on HTLV-II seropositive subjects including 97 U.S. blood donors without major
risk factors for HTLV-II infection, 53 injection drug users (IDU), and 10 American Indian blood donors. Three new HTLV-II
RFLP types were confirmed with DNA sequencing and phylogenetic analysis. HTLV-II RFLP type a0 (Switzer classification)
was associated with older age [adjusted odds ratio (OR) 1.06 per year of age, 95% confidence interval (CI) 1.02–1.09] and with
Black (OR 5.24, 95% CI 1.90–14.47) and White (OR 4.43, 95% CI 1.67–11.75) race/ ethnicity. These data are consistent with an
age–cohort effect for HTLV-II RFLP type a0 among older White and Black IDU and blood donors. This finding could be
explained by an epidemic of non-a0 HTLV-II RFLP types among younger persons of Hispanic and other race/ethnicity,
superimposed upon endemic HTLV-II RFLP type a0 among older Black and White persons. © 1998 Academic Press
INTRODUCTION
Human T-lymphotropic virus type II (HTLV-II), first iso-
lated (Kalyanaraman et al., 1982) and characterized
(Chen et al., 1983) in the early 1980’s, is molecularly
related to other primate T-lymphotropic viruses including
HTLV-I and related simian viruses (Vandamme et al.,
1996; Cereseto et al., 1996). It is endemic in some but not
all Amerindian tribes in North, Central, and South Amer-
ica, but has also become epidemic among injection drug
users (IDU) in North and South America and, to a lesser
extent, in Europe (Hall et al., 1996). Seroepidemiologic
studies of HTLV-II among Amerindians reveal overall
prevalence of 3 to 30% (Hjelle et al., 1994; Maloney et al.,
1992; Vitek et al., 1995). Mother to child transmission is
indicated by concordance of serostatus and viral se-
quence between mother and children (Vitek et al., 1995;
Lal et al., 1993), and an increase in seroprevalence with
age is consistent with sexual transmission (Vitek et al.,
1995). Among IDU, there is evidence that the virus has
been epidemic since at least the 1970’s in North America
(Biggar et al., 1991; Khabbaz et al., 1991), with preva-
lences ranging from 1 to 18% in various North American
cities (Khabbaz et al., 1992). Ongoing transmission of
HTLV-II in the United States may be inferred from the
strong association of HTLV-II seroprevalence with the
duration of drug injection (Feigal et al., 1991), and from
recent data revealing an HTLV-II sero-incidence of 0.7
per 100 person–years among IDU (Vlahov et al., 1995).
Further complicating the epidemiologic picture is the
sporadic demonstration of HTLV-II in Africans, including
prostitutes in Ghana (Igarashi et al., 1993) and Cameroon
(Mauclere et al., 1995), a family cluster in Gabon (Tuppin
et al., 1996), and the isolated Central African Bambuti and
Bakola pygmy tribes (Goubau et al., 1992; Gessain et al.,
1995).
Thus, HTLV-II appears to be an endemic infection of
ancient people in both Africa and the Americas. It has
also been epidemic among IDU over a period of at least
20 years (Biggar et al., 1991), and may be considered an
unrecognized precursor of the HIV epidemic. However,
several important questions concerning the modern ep-
idemiology of HTLV-II remain to be answered. When and
from which endemic population did HTLV-II emerge to
infect IDU? Are there populations in the United States
with endemic HTLV-II other than Amerindians? And fi-
nally, to what extent has HTLV-II spread beyond Amerin-
dians and IDU into the general North American popula-
tion by means of sexual and maternal child transmis-
sion?
Restriction fragment length polymorphism (RFLP) has
recently been applied to the molecular subtyping of
HTLV-II (Switzer et al., 1995; Eiraku et al., 1995). The
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literature clearly indicates that RFLP types a0 and a3
[classification of Switzer and Heneine (Switzer et al.,
1995), phylogroup A-III], predominate among IDU but
are rare among Amerindians, whereas RFLP types b5
is almost exclusively found among Amerindians (Swit-
zer et al., 1995). In addition, overall HTLV-II seropreva-
lence is highest among older, Black and Hispanic IDU
in eastern and western U.S. cities (Khabbaz et al.,
1992; Feigal et al., 1991) groups with little apparent
contact with American Indians. These observations
led us to the hypothesis that Indians may not be the
only source of the HTLV-II epidemic among IDU. We
sought an endemic focus of HTLV-II among infected
U.S. blood donors without major risk factors, and com-
pared the prevalence of HTLV-II RFLP types among
young and old IDU to search for evidence of an age–
cohort effect for HTLV-II infection.
RESULTS
Study population
The study population consisted of 160 individuals, in-
cluding 97 subjects from the Retrovirus Epidemiology
Donor Study (REDS) cohort without major risk factors for
HTLV-II, 53 young and old IDU from the San Francisco
emergency room, and 10 samples from American Indian
blood donors. The demographic characteristics of the
subjects, by group, are given in Table 1. The median age
of the subjects was 34 (range 18 to 78), and roughly two
thirds of the subjects were female.
RFLP analysis
The HTLV-II RFLP types of the study population, as
determined by RFLP, are given in Table 2, with represen-
tative photographs in Fig. 1. RFLP type a0 was most
commonly observed, with 121 (76%) of all subjects clas-
sified in this group, followed by b4 (n 5 12, 8%), b5 (n 5
12, 8%), a3 (n 5 5, 3%). We observed three low risk
subjects with RFLP type a5, all of whom were former
blood donors from Los Angeles: a 22-year-old White
male, a 38-year-old Hispanic female, and a 57-year-old
American Indian male. We also found one San Francisco
IDU with the a2 RFLP type and two American Indians
with the a7 RFLP type.
Four specimens representing three potential new RFLP
types could not be classified into the RFLP classification of
Switzer and Heneine (Switzer et al., 1995) (see Fig. 1).
These included two ‘bx‘ specimens (samples 6–4 from a
32-year-old Hispanic female and 4–10 from a 31-year-old
White female, both from San Francisco, IDU) which gave a
b4 RFLP pattern except that they were cut with SauI at a site
similar to the ‘‘a’’ RFLP types; one ‘‘by’’ specimen (sample
15–21 from a 29-year-old low-risk Black female from San
TABLE 1















Less than 30 10 (10) 0 3 (30) 13 (8)
30–39 41 (42) 23 (43) 3 (3) 67 (42)
40–49 30 (31) 0 2 (20) 32 (20)
50–59 7 (7) 25 (47) 2 (20) 34 (21)
60 plus 9 (9) 5 (9) 0 14 (9)
Sex
Male 25 (26) 33 (62) 4 (40) 62 (39)
Female 72 (74) 20 (38) 6 (60) 98 (61)
Race/ethnicity
White 40 (41) 15 (28) 0 55 (34)
Black 34 (35) 30 (57) 0 64 (40)
Hispanic 17 (18) 8 (15) 0 25 (16)
Asian 2 (2) 0 0 2 (1)
Indian 2 (2) 0 10 (100) 12 (8)
Missing 2 (2) 0 0 2 (1)
City
Washington/Baltimore 14 (14) 0 1 (10) 15 (9)
Detroit 8 (8) 0 0 8 (5)
Oklahoma City 6 (6) 0 9 (90) 15 (9)
San Francisco 18 (19) 53 (100) 0 71 (44)
Los Angeles 51 (53) 0 0 51 (32)
Note. Percentages may not add to 100 due to rounding.
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Francisco) with a b5 pattern except that it had a novel
Eco47III restriction site; and one ‘‘bz’’ specimen (sample
9–17 from a 49-year-old low-risk White female from Detroit)
with a b4 pattern except that it had three rather than two
BanII sites. All new RFLP types were confirmed on subse-
quent proviral DNA sequencing.
TABLE 2


















A-III a0 73 (75) 45 (85) 3 (30) 121 (76)
A-III a2 0 1 (2) 0 1 (1)
A-III a3 3 (3) 2 (4) 0 5 (3)
A-II a5 3 (3) 0 0 3 (2)
A-II/IIIa a7 0 0 2 (20) 2 (1)
All RFLP type a 79 (81) 48 (91) 5 (50) 132 (83)
B-IIb b4 10 (10) 2 (4) 0 12 (8)
B-II ‘‘bz’’ 1 (1) 0 0 1 (1)
B-III b5 6 (6) 1 (2) 5 (50) 12 (8)
B-III ‘‘by’’ 1 (1) 0 0 1 (1)
B-New ‘‘bx’’ 0 2 (4) 0 2 (1)
All RFLP type b 18 (19) 5 (9) 5 (50) 28 (18)
Note. Percentages may not add to 100 due to rounding.
a The two a7 RFLP subtypes and the PH230CAM sequences were related to both A-II and A-III in our phylogenetic analysis.
b The literature classifies RFLP subtype b4 in the B-II phylogroup; however, the one b4 sequenced in the current study clustered in the B-III group.
FIG. 1. Restriction fragment length polymorphism (RFLP) patterns for representative specimens. Photos represent the products of restriction
cleavage with enzymes AvaII, BanII, Eco47III, SauI, DraII, and SacII electrophoresed on either 2% agarose or 1% agarose plus 2% low melting point
agarose and visualized with ethidium bromide. For each panel, the lanes are as follows: molecular weight standard in 100 bp increments, negative
control a0 specimen without enzyme, specimens representing RFLP types a0, a2, a3, a5, and a7, specimens representing RFLP types b4 and b5, and
new b RFLP type samples ‘‘bx’’, ‘‘by’’, and ‘‘bz’’. The ‘‘bz’’ lanes from the AvaII and SauI panels were added to the photograph from a separate gel.
Restriction with XhoI is not shown since it was positive only in the one a2 specimen.
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DNA sequence data
We chose to clone and sequence the 672-bp nested
polymerase chain reaction (PCR) product from one spec-
imen in each of the more common RFLP types that we
observed (a0, a2, a3, b4, and b5) plus two a5, two a7, and
all four specimens in the three novel RFLP types. All
sequences were unique, although the two specimens in
the new RFLP type bx RFLP type differed by only 2 bp.
Phylogenetic analyses of the 625-bp long terminal repeat
(LTR) segment using both the DNAPARS and the neigh-
bor-joining methods gave similar results; the DNAPARS-
generated phylogenetic tree is shown in Fig. 2a. Com-
FIG. 2. Phylogenetic analyses. The analyses were restricted to a 625 bp region of the HTLV-II LTR because sequence information from this fragment was most
widely available from other studies. The 13 samples from this study were compared to 39 published sequences (see Methods). Risk groups are designated by the
following abbreviations: OkInd, Oklahoma Indian; LoRsk, Low risk blood donor; SFIDU, San Francisco injection drug user. Phylogenetic subgroups on the right of
the figures are based upon the classification of Switzer et al. (1996). (a) This phylogenetic tree was constructed using the DNAPARS program from the Phylip package
(see Methods) with bootstrap values from a separate 200 iteration bootstrap model inscribed at the branch points. (b) The second tree was constructed using the
MEGA program (see Methods) using Kimura two-parameter distance and 1000 bootstrap iterations. Horizontal branch lengths are drawn to scale; the bar represents
0.01 nucleotide substitutions per site or 1% divergence. Vertical separations are for clarity only.
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plete separation of the HTLV-II-A and -B phylogroups
was obtained (bootstrap value 100%).
Within the A group, the phylogroup A-I Navajo isolate
NAVDS was well separated from all other A isolates
(bootstrap 99%). Separate subgroups within the A group
included the AII phylogroup (a5–a6 RFLP types) with
Brazilian Kayapo and the Ghanian prostitute GHKT, the
two a5 RFLP samples from the current study (samples
11–15 and 12–8) and the son of a Mexican prostitute
(mexy17); the AIII phylogroup including the MO prototype
as well as the a3 (sample 10–18), a2 (sample 6–2), and a0
(sample 5–5) RFLP types from the current study (boot-
strap 82% for the A-II/A-III separation). In contrast to
previous reports, our phylogenetic analysis classified the
Cameroonian prostitute PH230CAM and our two a7
RFLP types (samples 15–5 and 15–8) into a small group
related to both phylogroups A-III and A-II.
Within the B group, the B-III phylogroup included sev-
eral Amerindian isolates, including our b5 (14–17) and by
(15–21) RFLP types, and, surprisingly, our b4 (12–7) iso-
late which should have been located in the B-II cluster
with other published b4 samples. The bootstrap value for
FIG. 2—Continued
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the separation between the JG (phylogroup B-I) sample
from New York and the B-II samples was not strong.
Phylogroup B-II included a number of isolates from New
York, Spanish, and Italian IDU as well as our new bz
(9–17) RFLP type. Finally our two new bx (4–10, 6–4)
samples were separate from the B-I, B-II, and B-III clus-
ters (bootstrap 5 53%) and the B-IV phylogroup (boot-
strap 5 41%), which included wyu1 from a Colombian
Wayuu Indian and G12 from a Guaymi Indian.
The final phylogenetic analysis with the MEGA pro-
gram yielded a tree (Fig. 2b) similar to that of the previ-
ous methods, but with an estimation of genetic distance
given by the scale bar. In this tree, phylogroups B-II and
B-III appear to be poorly separated. However, our new bx
(4–10, 6–4) samples are still weakly separated from phy-
logroups B-II/B-III and B-IV with bootstrap values of 50
and 54%, respectively, similar to those of the DNAPARS
analysis.
Epidemiologic analysis
Because 76% of subjects in the current study were the
IDU-associated RFLP type a0 in the Switzer and Heneine
classification (Switzer et al., 1995), we chose to analyze
the demographic characteristics of this RFLP type in
comparison to that of all others combined. The propor-
tion of HTLV-II RFLP type a0 among all HTLV-II RFLP
types is shown for different subgroups of subjects in Fig.
3. RFLP type a0 was relatively more common among
older than younger subjects [adjusted odds ratio (OR)
1.05 per year of age, 95% confidence interval (CI) 1.02–
1.09]; there was no RFLP type difference by gender (data
not shown). Both Black subjects (OR 5.81, 95% CI 2.25–
14.92) and White subjects (OR 3.80, 95% CI 1.53–9.45)
had a higher proportion of RFLP type a0 compared to
combined Hispanic, American Indian, and Asian sub-
jects. The racial difference was even more marked when
the analysis was limited to women; 84% of Black women
(OR 7.20, 95% CI 1.99–26.09) and 81% of White women
(OR 5.83, 95% CI 1.84–18.54), compared to 7/13 Hispanic,
0/2 Asian, or 2/6 American Indian women (43% com-
bined), were RFLP type a0.
Within the IDU subject group, the prevalence of RFLP
type a0 was 74% in those under 40 compared to 93% in
those over 40 (P 5 0.06, Fishers exact test). There was
no difference in a0 prevalence between the 7 HIV sero-
positive and the 46 HIV seronegative IDUs. Within the
‘‘low risk’’ subject group (the only group with representa-
tion in all metropolitan areas) the prevalence of RFLP
type a0 was highest in the Washington/Baltimore area
(100%), intermediate in the Oklahoma City (83%), San
Francisco (83%), and Detroit (75%) areas, and lowest in
the Los Angeles (65%) area. The a0 prevalence for Los
FIG. 3. The proportion of HTLV-II RFLP type a0 among all HTLV-II RFLP types, by age, race, study group and geographic location (center). All 160
subjects are included in each analysis except for the geographic analysis in the third panel, which includes only the ‘‘low risk’’ REDS subjects because
they were the only group represented in all geographic locations.
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Angeles was significantly lower than that of the other
four metropolitan areas combined (OR 0.28, 95% CI 0.10–
0.77). Because of the unexpectedly high RFLP type a0
prevalence among the low risk subjects, we also exam-
ined data on sexual behavior in this group. Although the
mean number of lifetime male partners was over 10 for
female low risk subjects, there was no difference in the
number of partners between RFLP type a0 subjects ver-
sus non-a0 female subjects.
Logistic regression modeling was performed to con-
trol for potential confounding; however, the complexity of
the models was limited by the moderate sample size of
the study. In a model which included age, sex, race, and
geographic location the variables significantly associ-
ated with HTLV-II RFLP type a0 were age (OR51.06 per
year, 95% CI 1.02–1.09), Black race (OR55.23, 95% CI
1.90–14.43), and White race (OR54.28, 95% CI 1.58–11.57)
(both versus combined Hispanic/Indian/Asian race). The
source of the subject (low risk vs. IDU vs. American
Indian) was not associated with RFLP type a0 and was
not retained in the final model. In a separate model for
the low risk subjects with good geographic representa-
tion, subtype a0 was still associated with age (OR51.06
per year, 95% CI 1.01–1.12) and Black race (OR54.69, 95%
CI 1.02–21.51), but only nonsignificantly with White race
(OR52.87, 95% CI 0.73–11.23) and inversely with Los
Angeles (OR50.42, 95% CI 0.13–1.39).
DISCUSSION
Our demonstration of HTLV-II RFLP types a2, a5, and
a7 in North American IDU, low risk blood donors and
Indians, respectively, adds to the reported number of
these rare RFLP types in the United States. RFLP type a2
has previously been reported in five Norwegian IDU and
two blood donors from Atlanta, Georgia (Switzer et al.,
1995). Given the high prevalence of HTLV-II among U.S.
IDU (Khabbaz et al., 1992), it is more likely that RFLP type
a2 was introduced from U.S. into Norwegian IDU, rather
than vice versa. The opposite is probably true for RFLP
type a5, which is most prevalent among the Kayapo,
Kraho, and other Brazilians. This RFLP type has previ-
ously been reported in a prostitute from Ghana and the
child of a Mexican prostitute (Switzer et al., 1996), and
our finding of this RFLP type among three low risk U.S.
blood donors in Los Angeles implies the penetration of
the RFLP type into North America. Finally, our data on
HTLV-II RFLP type a7 among two American Indians from
Oklahoma is difficult to reconcile with the single previous
isolation of this RFLP type from a prostitute in Cameroon
(Mauclere et al., 1995).
We have also identified three new HTLV-II RFLP types
among our low risk blood donors and IDU. Our new by
genotype differed from the b5 RFLP type only in having
an extra Eco47III restriction site and was located near b5
in the phylogenetic analysis. The one bz and the two bx
samples differed from the b4 RFLP type only in having
extra BanII and SauI restriction sites, respectively. Sam-
ple bz was grouped in the genotype B-II with other
published RFLP type b4 sequences, whereas the two bx
samples formed a new genotype intermediate between
the Wayuu/Guaymi Indian B-IV genotype and the other B
genotypes. The case of our sample 12–7 which had an
RFLP b4 phenotype, but was located with other pub-
lished b5 rather than b4 sequences in the phylogenetic
analysis, was the single exception in our study to the
correspondence between RFLP and sequence analysis.
These data indicate that RFLP is useful in screening for
new RFLP types. However, novel RFLP types based upon
single restriction enzyme differences could be caused by
PCR errors and should be interpreted with caution. Phy-
logenetic analysis based upon proviral DNA sequence
remains the gold standard for defining new HTLV-II RFLP
types.
The distribution of RFLP types in both the low risk and
IDU groups was similar to that of samples from multiple
U.S. sources (Switzer et al., 1995), or New York blood
donors (Eiraku et al., 1995) in the two other major studies
using RFLP of the LTR region to classify HTLV-II RFLP
types. Thus, although all low risk subjects denied IDU,
sex with an IDU and blood transfusion, their infections
probably originated indirectly from the large pool of IDU-
related HTLV-II in the United States, probably by sexual
transmission. This inference is supported by the prepon-
derance of females in the low risk group compared to the
male excess in the IDU group and by the relatively high
number of lifetime sexual partners in these females.
Previously published data from the REDS cohort indicate
that the number of lifetime sexual partners is a risk factor
for HTLV-II infection independent of IDU or sex with an
IDU (Schreiber et al., 1997).
We found that the distribution of HTLV-II RFLP type a0
was not uniform among the subjects, being significantly
higher in older vs. younger, and in Black and White vs.
other race subjects. There was also a statistically insig-
nificant lower prevalence of RFLP type a0 in subjects
from Los Angeles. Within the IDU group, a0 prevalence
was higher in subjects over 40 years old compared to
subjects less than 40 years old, a finding that persisted
after controlling for sex and race. These data are con-
sistent with an age–cohort effect for HTLV-II RFLP type
a0 among older White and Black IDU and blood donors.
Such an age–cohort effect could be produced by either
an historic epidemic of HTLV-II RFLP type a0 or a more
recent epidemic of non-a0 RFLP types. Another study
has reported age, race, and geographic variation in
HTLV-II prevalence among IDU, although HTLV-II sub-
type was not measured (Briggs et al., 1995).
The demonstration of a cohort effect for RFLP type a0
has implications for understanding the origin of HTLV-II
infection in the United States. There is little evidence in
the literature for RFLP type a0 infection among American
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Indians (Switzer et al., 1995; Eiraku et al., 1995). Since the
duration of IDU is correlated with age among IDU (Feigal
et al., 1991), data from the current study suggest that
HTLV-II RFLP type a0 was endemic among both Black
and White IDU at least 20 to 30 years ago, perhaps from
an unrecognized endemic focus in these racial/ethnic
groups. Younger subjects, and those of Hispanic, Asian,
and American Indian race/ethnicity, had a higher propor-
tion of non-a0 RFLP types, suggesting the subsequent
admixture of these RFLP types with the predominant a0
RFLP type. In such a scenario, the introduction of HTLV-II
from American Indians or another source into IDU is
probably a more recent phenomenon than inferred by
other authors (Hall et al., 1996; Heneine et al., 1996).
Further RFLP subtyping of older, non-IDU HTLV-II sero-
positives in the future may confirm our hypothesis of a
preexisting endemic focus of HTLV-II RFLP type a0 in the
United States.
An alternate explanation for the HTLV-II epidemic
among IDU would be a founder effect, initiated by the
contact between a rare Indian with RFLP type a0 and an
IDU more than 30 years ago. This RFLP type then ex-
panded, only to be admixed with other HTLV-II RFLP
types among younger IDU. Although there is little data on
the relative viral load or transmission efficiency of differ-
ent HTLV-II RFLP types, another possibility is greater
epidemiologic fitness of RFLP subtype a0. One study has
reported a similar distribution of RFLP types among
HTLV-II infected men who did or did not transmit their
infection to their long-term sexual partner (Kaplan et al.,
1996), the correlation between viral load and HTLV-II
RFLP type was not examined. Additional studies of the
transmission and pathogenesis of HTLV-II infection
should include information on RFLP types.
In conclusion, we report novel and unusual HTLV-II
RFLP types among both low risk blood donors and IDU in
the United States, suggesting that the epidemiology of
this virus is complex and not determined solely by ge-
ography or race/ethnicity. We have also found evidence
for an age–cohort effect of HTLV-II RFLP type a0 among
older HTLV-II infected subjects, and an association of
this RFLP type with Black and White race/ethnicity. This
finding could be explained by an epidemic of non-a0
HTLV-II RFLP types among younger persons of Hispanic
and other race/ethnicity, superimposed upon low-level




Three sets of samples from individuals with confirmed
HTLV-II seropositivity were studied. First, in a search for
a non-Indian endemic focus of HTLV-II in the United
States, we selected only those subjects with negative
questionnaire responses to questions about IDU,
sex with an IDU, and receipt of a blood transfusion
(Schreiber et al., 1997) from among 404 HTLV-II positive,
HIV seronegative blood donors enrolled in the REDS
cohort from 1990 to 1992 (Murphy et al., 1997). Second, to
study temporal trends of HTLV-II among IDU, we studied
HTLV-II positive samples from young and old IDU en-
rolled in another study of San Francisco emergency
room patients in 1993–1994, selected without regard to
HIV status. Finally, we also studied a small number of
specimens from American Indian blood donors collected
by the REDS study in 1991–1994. Risk factor information
was not available from the last group because they were
not enrolled into the prospective cohort. Either Ficoll-
separated peripheral blood mononuclear cells or white
blood cell pellets were obtained from frozen repositories,
and demographic and risk factor data were obtained
from the source studies. The study protocol was ap-
proved by the human subjects committee of the Univer-
sity of California San Francisco.
PCR
Cellular samples equivalent to 0.5 ml of whole blood
for the WBC pellet specimens or 1.5 million cells for
the PBMC specimens were treated with a saponin
lysis sample preparation kit (Roche Molecular Sys-
tems, Nutley, NJ). Nested PCR of the HTLV-II LTR
region was then performed on lysed sample according
to the method of Switzer et al. (1995). Initial primers
BSQF6 and BSDR3 amplified a 712-bp LTR fragment,
followed by the nested primers BSQF2 and BSDR4 to
amplify a 672-bp product. The initial PCR mixture con-
sisted of 0.2 mM dNTP (Pharmacia, Uppsala, Sweden),
103 buffer (Perkin–Elmer–Cetus, Gaithersburg, MD),
each primer at 10 mM, 2.5 units of Taq polymerase
(Perkin–Elmer–Cetus), and water in a total volume of
100 ml. No magnesium was added because of preex-
isting magnesium in the lysis buffer. The nested PCR
mixture consisted of the same reagents plus MgCl2
(Perkin–Elmer–Cetus) at 1.25 mM final concentration.
Following denaturation at 94°C for 5 min, the reaction
mixture were cycled 35 times at 94°C for 1 min, 55°C
for 1 min and 72°C for 1 min with an extension time of
2 s per cycle, followed by a final extension at 72°C for
7 min, using a Perkin–Elmer 4800 thermocycler. Phys-
ical separation was maintained between the sample
preparation and post-PCR manipulations. The pres-
ence of a PCR product of the expected size was
assessed by electrophoresis on a 2% agarose (Gibco
BrL, Gaithersburg, MD) gel with ethidium bromide.
RFLP
RFLP analysis was performed on all specimens with
positive PCR results using the enzymes DraII, XhoI, AvaII,
SauI (also called AocI) (Boehringer, Mannheim, Ger-
many), and BanII, Eco47III, and SacII (Promega, Madi-
432 MURPHY ET AL.
son, WI). The only difference from the RFLP method of
Switzer and Heneine (Switzer et al., 1995) was that BglI
was not utilized because this enzyme did not add to the
discrimination provided by the above enzymes. The
nested PCR product was not purified prior to RFLP. Re-
action conditions included 2 to 4 ml of nested PCR
product, 5–10 units of enzyme plus 103 enzyme-specific
buffer provided by manufacturer, at a final concentration
of 13. Incubation was for 2 h at 37°C, and reaction
products were visualized either on 2% agarose or 1%
agarose plus 2% NuSieve low melting point agarose
(FMC Bio Products, Rockland, ME) with ethidium bro-
mide.
Cloning and sequencing
Twenty-five microliters of nested HTLV-II LTR PCR
product from selected samples was subjected to 2%
agarose gel electrophoresis and the resulting 672 bp
band was excised and purified using a Geneclean kit
(Bio 101, La Jolla, CA). The HTLV-II DNA was bluntly
ligated into an ampicillin-resistant pCR Script amp SK1
plasmid (Stratagene, La Jolla CA) and then transfected
into HB101 Escherichia coli (Gibco BrL) using a heat
shock methodology and plated onto ampicillin media.
Positive colonies were selected by filter hybridization to
HTLV-II LTR probes 27-LTRII and 481RM (Mauclere et al.,
1995) labeled with 32P (Amersham, Little Chalfont, Buck-
inghamshire, UK). Plasmid DNA was purified using Qia-
gen midiprep kits (Qiagen, Milden, Germany). DNA se-
quencing was done on one clone from each sample
using the chain termination method with the Sequenase
2.0 kit (USB, Beverly, MA), universal primers T3 and T7
and HTLV-II LTR primers 27-LTRII and 481RM (Mauclere
et al., 1995). Sequence ladders were read independently
by three investigators. The 13 sequences have been
registered with GenBank under accession numbers
U73008 through U73010, U73012 and U73014 through
U73022.
Phylogenetic and statistical analysis
The analysis was restricted to a 625 bp region of the
HTLV-II LTR because sequence information from this
fragment was most widely available from other studies.
Comparison sequences were chosen with the goal of
including all published HTLV-II LTR sequences which
included this 625 bp region (Goubau et al., 1992; Switzer
et al., 1996; Vallejo et al., 1996), and included: kay139,
kay73 from Kayapo Indians and BRAZ.A21 from Brazil,
GHKT from a Ghanian prostitute, mexy17 from a Mexi-
can, LA8A from Los Angeles, ATL18 from Atlanta, nor2n
from Norway, MO the HTLV-IIMoT prototype, puebrb and
puebag from Pueblo Indians, PH230PCAM from a Cam-
eroonian prostitute, NAVDS from a Navajo, NRA the
HTLV-IINRA prototype, sem1050 and sem1051 are from
Seminole Indians, wyu1 and wyu2 are from Wayuu Indi-
ans, pygcam1 is from a Cameroonian Pygmy, Penn7A
from Pennsylvania, VA, GU, ITA50A, ITA47A are from
Italian IDU; JG and NY185 are from New York IDU; RVP,
324, DP, span130, BF, RC, span129, 130, JA, AA, JL, and
JAN are from Spanish IDU; G12 is from a Panamanian
Guaymi Indian; and ATK is a prototype HTLV-I isolate as
an out-group.
Multiple alignments were performed using the
Clustal W program (Thompson et al., 1994). Sites in-
cluding only gaps introduced by the outgroup were
eliminated from the final aligned sequences. We first
used two different methods to generate phylogenetic
trees: the maximum parsimony method using the
DNAPARS program, and the neighbor-joining method
(NEIGHBOR program) with modified Kimura 2-parameter
distance, both from the PHYLIP package Version 3.52c
(Joseph Felsenstein, joe@genetics.washington.edu) . The
SEQBOOT program was used to generate 200 data sets
that are randomly resampled versions of the previously
aligned sequences. For both the maximum parsimony and
neighbor-joining methods, a consensus tree was con-
structed using the CONSENSE program with the ‘majority
rule‘ criteria. Bootstrap values given on the trees were
percentage values based upon 200 bootstrap iterations. In
these trees, the tree branch lengths have no particular
meaning. To remedy this, we performed a final analysis
using the molecular evolutionary genetic analysis (MEGA
Version 1.01) program (S. Kumar, K. Tamura, and M. Nei,
Institute of Molecular Evolutionary Genetics, Pennsylvania
State University, University Park, PA) to construct a consen-
sus tree obtained by the neighbor-joining method (using
Kimura two-parameter distance and 1000 bootstrap itera-
tions), with estimated branch lengths.
Epidemiologic and RFLP type data were processed
using SAS software (Statistical Analysis System, Cary,
NC). Univariate analyses were performed using 2 3 2
tables, and associations were tested using the Fishers
exact test and odds ratios (OR) with exact 95% confi-
dence intervals. Multivariate models were analyzed us-
ing the SAS Proc Logist procedure.
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